congress
presentations

Alzheimer’s Association International Conference (AAIC)

Philadelphia, PA
July 28 – Aug. 1, 2024

PDF screenshot

AXS-05 | Alzheimer’s Disease-Related Agitation

Featured Research Session #87680 Sunday, July 28, 2024: 4:15 PM – 5:45 PM EDT: Efficacy and Safety Of AXS-05 in Alzheimer’s Disease Agitation: Results From ACCORD, a Phase 3, Double-Blind, Placebo-Controlled, Relapse Prevention Study

view/download

PDF screenshot

AXS-05 | Alzheimer’s Disease-Related Agitation

Clinical Profile of AXS-05 in Treating Alzheimer’s Disease Agitation: Results from the Phase 2/3 Development Program

AXS-05 | Alzheimer’s Disease-Related Agitation

Dr. Jeffrey L. Cummings, MD, ScD describes the "Clinical Profile of AXS-05 (Dextromethorphan-Bupropion) in Treating Alzheimer’s Disease Agitation: Results From The Phase 2/3 Development Program" AAIC 2024 poster

view

This site is intended for registered attendees of the respective Congress.
This site contains scientific presentations on investigational products and/or investigational uses of approved products for Axsome or its partners sponsored studies.
The safety and efficacy of investigational products and/or investigational uses of approved products has not been established and such investigational products/uses have not and may not be approved for marketing by any health authority.
Marketing authorization, approval status, and prescribing information for approved products varies by country. Please seek further details from the health authority in your country such as approved product labeling.

AXSOME and its logos are trademarks or registered trademarks of Axsome Therapeutics, Inc. or its affiliates. Other trademarks are property of their respective owners.

© 2023 Axsome Therapeutics, Inc. All rights reserved. One World Trade Center, 22nd Floor, New York, NY 10007 info@axsome.com